Commentary.

The author comments on the paper which examines the determinants of competition in one drug class in Great Britain, Germany, France and the Netherlands over the period 1991-2002. The author said that the study estimates the demand structure between different brands having different payment schemes. He said that the paper makes some important initial progress on the issue of demand substitutability between brands and therapeutic competition for understanding the magnitude of innovative returns.